Last reviewed · How we verify
VTP-43742
At a glance
| Generic name | VTP-43742 |
|---|---|
| Sponsor | Vitae Pharmaceuticals Inc., an Allergan affiliate |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers and Psoriatic Patients (PHASE1, PHASE2)
- An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- VTP-43742 CI brief — competitive landscape report
- VTP-43742 updates RSS · CI watch RSS
- Vitae Pharmaceuticals Inc., an Allergan affiliate portfolio CI